Clinicopathological characteristics and survival results of patients with ultralow risk breast cancer.
Características clínico-patológicas y supervivencia de pacientes con cáncer de mama de riesgo muy bajo.
Breast cancer
Cribado mamográfico
Cáncer de mama
Enfermedad indolente
Indolent disease
Riesgo muy bajo
Screening mammography
Supervivencia
Survival
Ultralow threshold
Journal
Medicina clinica
ISSN: 1578-8989
Titre abrégé: Med Clin (Barc)
Pays: Spain
ID NLM: 0376377
Informations de publication
Date de publication:
28 10 2022
28 10 2022
Historique:
received:
03
09
2021
revised:
24
11
2021
accepted:
25
11
2021
pubmed:
20
2
2022
medline:
19
10
2022
entrez:
19
2
2022
Statut:
ppublish
Résumé
To identify subgroups with good progress over an extended period, we used diagnostic screening, tumour palpability, tumour phenotype, and node involvement. We identified patients with good progress by means of a descriptive, observational and retrospective study. Of 746 patients diagnosed with node-negative breast cancer between 2001 and 2015: 110 (14.75%) had non-palpable screening-diagnosed tumours; 88 (80%) were endocrine-sensitive, 10 (9.10%) were triple-negative and 11 (10%) were HER2. Only 3 patients developed metastases, and there were 4 deaths: 2 from breast cancer and 2 from other causes. The distant recurrence-free interval (DRFI) was 95.60%: 100% in 34 endocrine-sensitive histological grade 1 (equivalent to luminal A) tumours, and 94.40% (95% CI 86.76-102.04) in 54 grade 2-3 (luminal B) tumours. In triple-negative and HER2 cases, it was 100%. In tumours <1 cm it was 100%, and >1 cm it was 95.50% (95% CI 79.42-100.98). Patients with non-palpable tumours detected by mammogram screening have ultralow risk. The good progress in the luminal A, triple-negative, HER2, and less than 1 cm subgroups may explain the efficacy of the treatment but it also makes them candidates to de-escalation of their treatment.
Sections du résumé
BACKGROUND AND OBJECTIVE
To identify subgroups with good progress over an extended period, we used diagnostic screening, tumour palpability, tumour phenotype, and node involvement.
PATIENTS AND METHODS
We identified patients with good progress by means of a descriptive, observational and retrospective study.
RESULTS
Of 746 patients diagnosed with node-negative breast cancer between 2001 and 2015: 110 (14.75%) had non-palpable screening-diagnosed tumours; 88 (80%) were endocrine-sensitive, 10 (9.10%) were triple-negative and 11 (10%) were HER2. Only 3 patients developed metastases, and there were 4 deaths: 2 from breast cancer and 2 from other causes. The distant recurrence-free interval (DRFI) was 95.60%: 100% in 34 endocrine-sensitive histological grade 1 (equivalent to luminal A) tumours, and 94.40% (95% CI 86.76-102.04) in 54 grade 2-3 (luminal B) tumours. In triple-negative and HER2 cases, it was 100%. In tumours <1 cm it was 100%, and >1 cm it was 95.50% (95% CI 79.42-100.98).
CONCLUSIONS
Patients with non-palpable tumours detected by mammogram screening have ultralow risk. The good progress in the luminal A, triple-negative, HER2, and less than 1 cm subgroups may explain the efficacy of the treatment but it also makes them candidates to de-escalation of their treatment.
Identifiants
pubmed: 35181168
pii: S0025-7753(21)00715-6
doi: 10.1016/j.medcli.2021.11.008
pii:
doi:
Substances chimiques
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
spa
Sous-ensembles de citation
IM
Pagination
351-358Informations de copyright
Copyright © 2022 Elsevier España, S.L.U. All rights reserved.